701 related articles for article (PubMed ID: 17716505)
1. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
3. Dapsone hypersensitivity syndrome among leprosy patients in China.
Tian W; Shen J; Zhou M; Yan L; Zhang G
Lepr Rev; 2012 Dec; 83(4):370-7. PubMed ID: 23614255
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
5. Increase in the incidence of dapsone hypersensitivity syndrome--an appraisal.
Rao PN; Lakshmi TS
Lepr Rev; 2001 Mar; 72(1):57-62. PubMed ID: 11355519
[TBL] [Abstract][Full Text] [Related]
6. Side-effects of Isoprodian compared with WHO-MDT in rural Nepal.
van Brakel WH; Drever W
Lepr Rev; 1993 Sep; 64(3):276-80. PubMed ID: 8231610
[No Abstract] [Full Text] [Related]
7. A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing.
Wang N; Parimi L; Liu H; Zhang F
Am J Trop Med Hyg; 2017 May; 96(5):1014-1018. PubMed ID: 28167593
[TBL] [Abstract][Full Text] [Related]
8. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan.
Sheen YS; Chu CY; Wang SH; Tsai TF
J Dermatolog Treat; 2009; 20(6):340-3. PubMed ID: 19954390
[TBL] [Abstract][Full Text] [Related]
9. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
10. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.
Krismawati H; Irwanto A; Pongtiku A; Irwan ID; Maladan Y; Sitanggang YA; Wahyuni T; Tanjung R; Sun Y; Liu H; Zhang F; Oktavian A; Liu J
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008746. PubMed ID: 33064728
[TBL] [Abstract][Full Text] [Related]
11. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
12. Renal hypersensitivity vasculitis associated with dapsone.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Rabel-Filho OC; Martini-Filho D; Fontes CJ
Am J Kidney Dis; 2005 Oct; 46(4):e51-3. PubMed ID: 16183407
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
14. Causes of death among active leprosy patients in China.
Shen J; Liu M; Zhou M; Li W
Int J Dermatol; 2011 Jan; 50(1):57-60. PubMed ID: 21182503
[TBL] [Abstract][Full Text] [Related]
15. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
[TBL] [Abstract][Full Text] [Related]
16. Dapsone syndrome: an incomplete form.
Jaswal R; Thami GP; Kanwar AJ
Indian J Lepr; 1998; 70(2):229-30. PubMed ID: 9724867
[No Abstract] [Full Text] [Related]
17. Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
Singh H; Nel B; Dey V; Tiwari P; Dulhani N
Lepr Rev; 2011 Mar; 82(1):17-24. PubMed ID: 21644468
[TBL] [Abstract][Full Text] [Related]
18. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus.
Pai S; Munshi R; Nayak C
Indian J Pharmacol; 2017; 49(5):396-398. PubMed ID: 29515281
[TBL] [Abstract][Full Text] [Related]
19. A lethal case of the dapsone hypersensitivity syndrome involving the myocardium.
Hoogeveen RM; van der Bom T; de Boer HH; Thurlings RM; Wind BS; de Vries HJ; van Lent AU; Beuers U; van der Wal AC; Nellen FJ
Neth J Med; 2016 Feb; 74(2):89-92. PubMed ID: 26951355
[TBL] [Abstract][Full Text] [Related]
20. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
